Compare TransMedics Group Inc (TMDX) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Ulta Beauty Inc — how do they compare? TransMedics Group Inc trades at $87.08 (market cap $3.10B), while Ulta Beauty Inc trades at $531.85 (market cap $23.27B). The key difference: Ulta Beauty Inc is far larger — about 7.5× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| TMDX | ULTA | |
|---|---|---|
Market Cap | $3.10B | $23.27B |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $706.82 |
52-Week Low | $61.99 | $450.75 |
Enterprise Value | $3.49B | $25.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
ULTA stock trades at $532.14, down 3.01% today, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of $7.74, beating expectations, and maintains strong profitability with a 39.33% gross margin and 47.45% ROE. Recent news highlights Ulta's omnichannel growth strategy and the end of its Target partnership, viewed as a potential revenue opportunity by analysts.
Outlook is positive with a consensus price target of $618.29, representing 16% upside, supported by 56.53% analyst buy ratings. Risks include margin compression, with net income margin projected to drop to 9.35% in 2026, and volatile cash flows, as net cash flow turned negative in 2025. Investors should weigh strong fundamentals against competitive and execution risks in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
